Navigation Links
Advanced Instruments Signs License and Sensor Development Agreement With Cantimer, Inc.

MENLO PARK, Calif. and NORWOOD, Mass., Feb. 23 /PRNewswire/ -- Cantimer, Inc., and Advanced Instruments, Inc. today jointly announced that the two companies had signed a license and product development agreement. Under the terms of the license agreement, Advanced Instruments received an exclusive license to Cantimer's unique sensor technology for select applications in the biotech market. The Companies also entered into a Product Development Agreement for Cantimer to develop a specific sensor to integrate into Advanced Instruments' products for in-situ monitoring of osmolality in bioreactors and fermenters. The companies anticipate that a long term sensor supply agreement will follow the joint development effort and that developed products will be sold to end-users through Advanced Instruments' existing commercial network.  

"Monitoring osmolality is a critical control parameter in the biotech market. Traditionally this has been accomplished using discreet samples on a laboratory instrument. Cantimer's unique sensor technology makes it possible to measure osmolality in the bioreactor and in real time, reducing the possibility of product contamination and enabling tighter product quality control" said John Coughlin, CEO of Advanced Instruments. "The industry has been asking for this capability for many years and we believe Cantimer's technology will allow us to finally address their needs" he added.

Cantimer's sensor platform can be adapted to detect and measure a broad array of chemical and biological compounds of interest and has application in markets as large and diverse as life science research, point-of-care diagnostics, consumer health, bio-defense and environmental monitoring. The Company's technology enables the development of simple, portable devices that are robust, sensitive, low-cost, label-free and easy-to-use. In parallel to the development of its own first commercial product, a pocket device for non-invasive measurement and monitoring of changes in human hydration, the Company has undertaken a number of sensor development projects for strategic partners.

"Advanced Instruments has been a very supportive investor and an enthusiastic strategic partner", commented Robin Stracey, CEO of Cantimer, Inc. "We look forward to this joint development effort with great enthusiasm".

About Cantimer, Inc.

Cantimer is a privately-held, development stage company commercializing a patented, proprietary sensor technology platform having application in life science, bio-defense, environmental testing, point-of-care diagnostics and home health markets. The Company's first focus is on development and commercialization of point-of-care products for convenient, non-invasive, measurement and monitoring of human hydration status from saliva.

About Advanced Instruments, Inc.

Founded in 1955, Advanced Instruments, Inc. is the world's largest supplier of freezing-point cryoscopes and osmometers used in dairy, clinical, pharmaceutical, and biotechnology laboratories. The company is also a leading supplier of analytical instruments for the food and industrial microbiology markets. Based in Norwood, Massachusetts, USA, the privately held company also produces Fiske® Associates brand diagnostic instruments and operates Spiral Biotech, Inc., and Delta Instruments as wholly-owned subsidiaries. A worldwide network of direct sales people and independent distributors supports Advanced Instruments' products.

SOURCE Cantimer, Inc.

Back to top



SOURCE Cantimer, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
2. Advanced Life Sciences Previews 2010 Milestones
3. EPA Reaffirms Sugarcane Biofuel is Advanced Renewable Fuel with 61% Less Emissions than Gasoline
4. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
5. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
8. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
9. Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures
11. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
Post Your Comments:
(Date:11/24/2015)... ... ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, of ... since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to the ... of Iselin, N.J., is an extension specialist of turfgrass pathology in the department of ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... maintain healthy metabolism. But unless it is bound to proteins, copper is also ... Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology:
(Date:11/4/2015)... 4, 2015 --> ... published by Transparency Market Research "Home Security Solutions Market - ... 2015 - 2022", the global home security solutions market is expected ... 2022. The market is estimated to expand at a ... to 2022. Rising security needs among customers at homes, ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
(Date:10/27/2015)... Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ... so that they can be quantitatively analyzed with SMI,s ... Germany , October 28-29, 2015. SMI,s Automated Semantic ... eye tracking videos created with SMI,s Eye Tracking ...
Breaking Biology News(10 mins):